ODYY · Odyssey Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | $0 | $42.8K | $0 | $0 | $170.0K | $25.8K | - | - |
| SG&A | $181.9K | $303.2K | $117.3K | $120.5K | $519.8K | $320.9K | $437.3K | $501.4K | $1.06M | $1.31M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | $944 | - | - | - | - | - |
| Operating Income | ($181.9K) | ($303.2K) | ($129.1K) | ($156.6K) | ($580.3K) | ($372.4K) | ($1.16M) | ($847.2K) | ($1.09M) | ($1.49M) |
| Interest Expense | $412.4K | $95.3K | $102.2K | $141.6K | $190.9K | $102.2K | $141.6K | $190.9K | $189.4K | $194.2K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.60M) | ($483.4K) | ($251.7K) | ($220.1K) | ($1.02M) | ($842.3K) | $13.28M | ($538.0K) | ($1.28M) | ($1.67M) |
| EPS - Basic | ($0.03) | $0.00 | $0.00 | $0.00 | ($0.01) | ($0.01) | $0.14 | ($0.01) | ($0.02) | ($0.02) |
| EPS - Diluted | ($0.03) | $0.00 | $0.00 | $0.00 | ($0.01) | ($0.01) | $0.12 | ($0.01) | ($0.02) | ($0.02) |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $616.3K | $25.6K | $3.2K | $7.2K | $53.9K | $66.0K | $166.1K | $197.9K | $36.9K | $35.8K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.62M | $1.69M | $1.62M | $1.45M | $1.46M | $1.28M | $1.27M | $1.85M | $1.80M | $1.71M |
| Current Assets | $721.3K | $143.6K | $49.7K | $108.4K | $182.5K | $56.9K | $259.5K | $563.1K | $405.9K | $413.7K |
| Total Assets | $721.3K | $143.6K | $49.7K | $266.9K | $341.0K | $586.1K | $14.05M | $612.0K | $455.8K | $463.4K |
| Current Liabilities | $11.32M | $7.30M | $7.00M | $6.73M | $6.62M | $5.92M | $5.38M | $6.83M | $6.61M | $5.83M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($10.60M) | ($7.16M) | ($6.95M) | ($6.46M) | ($6.28M) | ($5.33M) | $8.67M | ($6.22M) | ($6.16M) | ($5.37M) |
| Retained Earnings | ($66.83M) | ($63.23M) | ($62.75M) | ($62.24M) | ($62.02M) | ($61.00M) | ($47.42M) | ($60.64M) | ($60.10M) | ($58.00M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($284.0K) | - | - | ($248.5K) | - | - | ($59.9K) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | $0 | - | - |
| Financing Cash Flow | - | $290.5K | - | - | $300.0K | - | - | $220.9K | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -499.3% | -336.6% | -506.3% | -82.5% | -298.8% | -143.7% | 94.5% | -87.9% | -281.7% | -360.7% |
| Return on equity | 34.0% | 6.8% | 3.6% | 3.4% | 16.2% | 15.8% | 153.1% | 8.7% | 20.9% | 31.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.06 | 0.02 | 0.01 | 0.02 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.07 |
| Quick ratio | 0.06 | 0.02 | 0.01 | 0.02 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.07 |
| Cash ratio | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.03 | 0.01 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.4x | -3.2x | -1.3x | -1.1x | -3.0x | -3.6x | -8.2x | -4.4x | -5.8x | -7.7x |
| Equity multiplier | -0.07 | -0.02 | -0.01 | -0.04 | -0.05 | -0.11 | 1.62 | -0.10 | -0.07 | -0.09 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -16.2% | 47.8% | 65.3% | 86.5% | 31.5% | 66.0% | 22.1% | 59.2% | 61.8% | 24.8% |
| Net income growth (YoY) | -1536.2% | 52.6% | 70.1% | - | -89.4% | 34.4% | - | 75.0% | 58.6% | 1.2% |
| EPS growth (YoY) | - | - | - | - | 0.0% | 50.0% | - | 66.7% | 50.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -64.0% | -14.0% | -30.4% | - | -1.0% | 13.4% | - | -15.5% | -32.6% | -28.5% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Odyssey Health against the 5 most active filers in the same SIC group.